Showing results (141-150 of 158) with videos related to

Sort By:
Pageof 16
Frontiers in Oncology|August 29, 2022
Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapiesHervé Lang, Claire Béraud, Luc Cabel, et al.
Oncogene|November 9, 2023
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trialCeline Callens, Manuel Rodrigues, Adrien Briaux, et al.
Analytical Chemistry|April 13, 2022
Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGSCeline Callens, Francois-Clement Bidard, Anaïs Curto-Taribo, et al.
Nature Communications|June 22, 2023
Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trialManuel Rodrigues, Giulia Vanoni, Pierre Loap, et al.
Journal of Clinical Pathology|September 29, 2021
Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohortFriederike Kullmann, Pamela L Strissel, Reiner Strick, et al.
NPJ Breast Cancer|January 18, 2022
Value of the loss of heterozygosity to BRCA1 variant classificationElizabeth Santana Dos Santos, Amanda B Spurdle, Dirce M Carraro, et al.
Nature Communications|October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.
International Journal of Cancer|March 13, 2019
A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancerFlorence Coussy, Leanne de Koning, Marion Lavigne, et al.
Nature Medicine|March 6, 2023
Evolution of synchronous female bilateral breast cancers and response to treatmentAnne-Sophie Hamy, Judith Abécassis, Keltouma Driouch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer PatientsAnne de la Rochefordiere, Maud Kamal, Anne Floquet, et al.
Pageof 16